Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03785015
Other study ID # ReASA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 14, 2019
Est. completion date February 28, 2024

Study information

Verified date June 2020
Source Chinese University of Hong Kong
Contact Ka Man Kee, MPH
Phone 85235053855
Email carmenkee@cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute upper gastrointestinal (GI) bleeding associated with the use of low-dose aspirin (ASA) is a major cause of peptic ulcer bleeding worldwide. Among survivors of acute myocardial infarction, a study of over 14,000 patients reported that the risk of life-threatening GI bleeding in the first two months is 7 times higher than that in the subsequent months. After endoscopic control of ulcer bleeding, most patients with cardiovascular (CV) diseases will need to resume ASA. However, the investigator found that immediate resumption of ASA saves life but at the expense of higher risk of recurrent bleeding. Peptic ulcer bleeding associated with ASA is a major cause of hospitalization in Hong Kong. Currently, ASA use has contributed to about one-third of the bleeding ulcers admitted to our hospital that serves a local population of 1.5 million. Accordingly, current international guidelines recommend early resumption of ASA but the optimal timing is unknown. Clinicians often face the dilemma: when should ASA be resumed? Furthermore, patients who suffer from acute peptic ulcer bleeding are often elderly patients with significant co-morbidities. Mortality in these patients remains high. Clinicians are facing an increasing number of patients who are on antiplatelet drugs or anticoagulants. The investigator proposes a open-label randomized-controlled trial to evaluate the optimal timing of resuming ASA in patients with CV diseases complicated by peptic ulcer bleeding. Patients will be randomized to resume the standard treatment within first few hours or only to resume the standard treatment 72 hours after endoscopic haemostasis.


Description:

Acute upper gastrointestinal (GI) bleeding associated with the use of low-dose aspirin (ASA) is a major cause of peptic ulcer bleeding worldwide. Among survivors of acute myocardial infarction, a study of over 14,000 patients reported that the risk of life-threatening GI bleeding in the first two months is 7 times higher than that in the subsequent months (1). After endoscopic control of ulcer bleeding, most patients with cardiovascular (CV) diseases will need to resume ASA. Clinicians often face the dilemma: when should ASA be resumed? Furthermore, patients who suffer from acute peptic ulcer bleeding are often elderly patients with significant co-morbidities. Mortality in these patients remains high. Clinicians are facing an increasing number of patients who are on antiplatelet drugs or anticoagulants. However, there are very limited data to guide the best timing for resumption of ASA in these high risk patients. To date, our group has conducted the only randomized controlled trial in the literature that has partially addressed this issue. Importantly, the investigator found that immediate resumption of ASA saves life but at the expense of higher risk of recurrent bleeding (2). Accordingly, current international guidelines recommend early resumption of ASA but the optimal timing is unknown. In the setting of acute GI bleeding, it is often a dilemma whether to stop or to restart these drugs. The balance between bleeding and thrombotic risks is difficult and treatment is often empirical and not evidence-based. The investigator aims to test the hypothesis that in ASA users complicated by peptic ulcer bleeding, withholding ASA till day 3 reduces the risk of recurrent bleeding compared to immediate resumption of ASA without a significant increase in mortality. References 1. Moukarbel GV, Signorovitch JE, Pfeffer MA et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009;30(18):2226-32. 2. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152(1):1-9.


Recruitment information / eligibility

Status Recruiting
Enrollment 436
Est. completion date February 28, 2024
Est. primary completion date February 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age >18 2. Patients with actively bleeding gastroduodenal lesions (peptic ulcer, bleeding erosions, or Dieulafoy's lesion) or ulcers showing other high risk stigmata (visible blood vessels or adherent clots) treated by endoscopic therapy 3. Subjects continue to require regular ASA or dual anti-platelet therapy for treatment of CV or cerebrovascular diseases after this bleeding episode Exclusion Criteria: 1. Patients who received ASA for primary prophylaxis 2. Unsuccessful endoscopic hemostasis of bleeding ulcers or ulcer perforation 3. Gastric outlet obstruction 4. Known sensitivity to PPIs 5. Previous partial gastrectomy or vagotomy 6. Patients need concomitant anticoagulant 7. Pregnant unless sterilization, menopause or last menstrual period within 7 days 8. Other co-morbidities or advanced age that will hinder the drug compliance or follow up 9. Malignancy on active treatment 10. Unable to give consent

Study Design


Intervention

Other:
Resume Aspirin within 12 hours
Resume the standard treatment within 12 hours after endoscopic haemostasis
Resume Aspirin 72 - 84 hours
Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis

Locations

Country Name City State
Hong Kong Prince of Wales Hospital Hong Kong

Sponsors (3)

Lead Sponsor Collaborator
Chinese University of Hong Kong Beijing Friendship Hospital, National Taiwan University Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrent peptic ulcer bleeding Recurrent peptic ulcer bleeding within 30 days of endoscopic treatment 30 days after endoscopic treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05060731 - Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding Phase 4
Recruiting NCT05949268 - Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel
Not yet recruiting NCT03243240 - Computed Tomography in Gastrointestinal Bleeding N/A
Completed NCT02595853 - Efficacy of a Novel Hemostatic Powder in GI Bleeding
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01434108 - Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding Phase 2/Phase 3
Completed NCT01424254 - The Effectiveness of Video-capsule Endoscopy in Gastrointestinal Bleeding of Obscure Origin Phase 3
Completed NCT05884931 - Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment N/A
Completed NCT01335516 - Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices N/A
Withdrawn NCT00401908 - Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding N/A
Recruiting NCT05024864 - HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in MI Patients N/A
Completed NCT05008640 - Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT03716466 - Evaluation of Prophylactic Endotracheal Intubation
Completed NCT05362227 - High-Volume Vs Low-Volume Preparation in Emergency Department N/A
Completed NCT02405286 - Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage N/A
Recruiting NCT00562445 - Adrenal Insufficiency in Critical Emergencies in Digestive Diseases N/A
Recruiting NCT05290857 - Anticoagulation After GI Bleeding Pilot Study and Registry N/A
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry
Completed NCT01415869 - Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients